SPRED1 Antikörper (AA 45-322)

Produktnummer ABIN7601769

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch SPRED1 in WB, ELISA, FACS, IF und ICC. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für SPRED1 Antikörper (AA 45-322) (ABIN7601769)

Target: SPRED1 (Sprouty-Related, EVH1 Domain Containing 1 (SPRED1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SPRED1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF), Immunocytochemistry (ICC)

Produktdetails anti-SPRED1 Antikörper

Bindungsspezifität: AA 45-322

Verwendungszweck: Anti-SPRED1 Antibody Picoband®

Kreuzreaktivität (Details): No cross-reactivity with other proteins

Produktmerkmale: Anti-SPRED1 Antibody Picoband® (ABIN7601769). Tested in WB, ICC/IF, Flow Cytometry, ELISA applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E.coli-derived human SPRED1 recombinant protein (Position: F45-K322). Human SPRED1 shares 89.9% amino acid (aa) sequence identity with mouse SPRED1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.25-0.5 μg/mL, Human
Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human
ELISA, 0.1-0.5 μg/mL
1. Ablain, J., Xu, M., Rothschild, H., Jordan, R. C., Mito, J. K., Daniels, B. H., Bell, C. F., Joseph, N. M., Wu, H., Bastian, B. C., Zon, L. I., Yeh, I. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science 362: 1055-1060, 2018. 2. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K. Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.-P., Cools, J., Marynen, P., Thomas, G., Yoshimura, A., Legius, E. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. (Letter) Nature Genet. 39: 1120-1126, 2007. 3. Brems, H., Pasmant, E., Van Minkelen, R., Wimmer, K., Upadhyaya, M., Legius, E., Messiaen, L. Review and update of SPRED1 mutations causing Legius syndrome. Hum. Mutat. 33: 1538-1546, 2012.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.

Details zu SPRED1

Target: SPRED1 (Sprouty-Related, EVH1 Domain Containing 1 (SPRED1))

Andere Bezeichnung: SPRED1

Hintergrund:

Synonyms: SPRED1, Sprouty-related, EVH1 domain-containing protein 1, Spred-1, hSpred1

Background: The protein encoded by this gene is a member of the Sprouty family of proteins and is phosphorylated by tyrosine kinase in response to several growth factors. The encoded protein can act as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. Defects in this gene are a cause of neurofibromatosis type 1-like syndrome (NFLS).

Molekulargewicht: 50 kDa

Gen-ID: 161742

UniProt: Q7Z699

Pathways: Positive Regulation of Response to DNA Damage Stimulus